-
Mashup Score: 8
High-risk non-muscle-invasive bladder cancer (NMIBC) presents high recurrence and progression rates. Despite the use of Bacillus Calmette-Guérin gold-standard immunotherapy and the recent irruption…
Source: www.tandfonline.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 11177Lu-Dotatate Is a Viable Treatment in Meningioma - 3 month(s) ago
Lutetium 177 dotatate showed activity and met the PFS end point in patients with surgery- or radiation-refractory grade 2/3 meningioma, per a phase 2 trial presented at ASTRO 2024.
Source: www.targetedonc.comCategories: General Medicine News, Hem/OncsTweet-
177Lu-Dotatate Is a Viable Treatment in Meningioma. @OncoAlert @myESMO @GrupoGetne https://t.co/cqLalWhNPo
-
-
Mashup Score: 7
Siemens Healthineers has concluded the acquisition from Novartis of Advanced Accelerator Applications Molecular Imaging, a European manufacturing and distribution network of diagnostic radiopharmaceuticals for positron emission tomography (PET) scans.
Source: www.siemens-healthineers.comCategories: General Medicine News, Hem/OncsTweet-
Siemens Healthineers Acquires Advanced Accelerator Applications Molecular Imaging https://t.co/xUpuQKvcAZ
-
-
Mashup Score: 2Tumors Leverage Liver Metabolism to Fuel Growth With Fructose - 3 month(s) ago
Dietary fructose fuels tumor growth indirectly, a new study shows, with the liver converting the sugar into lipids that cancer cells scavenge to construct membranes for division.
Source: aacrjournals.orgCategories: General Medicine News, Hem/OncsTweet-
RT @MarcusDGon: Tumors Leverage Liver Metabolism to Fuel Growth With Fructose @CD_AACR @ElieDolgin https://t.co/UjUuddluh2
-
-
Mashup Score: 1Imfinzi granted Priority Review in the US for patients with muscle-invasive bladder cancer - 3 month(s) ago
AstraZeneca’s supplemental Biologics License Application (sBLA) for Imfinzi (durvalumab) has been accepted and granted Priority Review in the US for the treatment of patients with muscle-invasive bladder cancer (MIBC). The Food and Drug Administration (FDA) grants Priority Review to applications for medicines that, if approved, would offer significant improvements over available options by demonstrating safety or efficacy improvements, preventing serious cond itions or enhancing patient compliance. 1 The
Source: www.astrazeneca.comCategories: General Medicine News, Hem/OncsTweet-
https://t.co/AIO6EM9Dys
-
-
Mashup Score: 65
Positive high-level results from the CAPItello-281 Phase III trial showed that AstraZeneca’s Truqap (capivasertib) in combination with abiraterone and androgen deprivation therapy (ADT) demonstrated a statistically significant and clinically meaningful improvement in the primary endpoint of radiographic progression-free survival (rPFS) versus abiraterone and ADT with placebo in patients with PTEN-deficient de novo metastatic hormone-sensitive prostate cancer (mHSPC). Overall survival (OS) data were
Source: www.astrazeneca.comCategories: General Medicine News, Hem/OncsTweet-
Truqap combination in PTEN-deficient metastatic HSPC demonstrated statistically significant and clinically meaningful improvement in radiographic progression-free survival in CAPItello-281 Ph III trial 👏👏 @GuardConsortium @OncoAlert https://t.co/cHKC2ddkmy
-
-
Mashup Score: 65
Positive high-level results from the CAPItello-281 Phase III trial showed that AstraZeneca’s Truqap (capivasertib) in combination with abiraterone and androgen deprivation therapy (ADT) demonstrated a statistically significant and clinically meaningful improvement in the primary endpoint of radiographic progression-free survival (rPFS) versus abiraterone and ADT with placebo in patients with PTEN-deficient de novo metastatic hormone-sensitive prostate cancer (mHSPC). Overall survival (OS) data were
Source: www.astrazeneca.comCategories: General Medicine News, Hem/OncsTweet-
Truqap combination in PTEN-deficient metastatic HSPC demonstrated statistically significant and clinically meaningful improvement in radiographic progression-free survival in CAPItello-281 Ph III trial 👏👏 @GuardConsortium @OncoAlert https://t.co/cHKC2ddkmy
-
-
Mashup Score: 65
Positive high-level results from the CAPItello-281 Phase III trial showed that AstraZeneca’s Truqap (capivasertib) in combination with abiraterone and androgen deprivation therapy (ADT) demonstrated a statistically significant and clinically meaningful improvement in the primary endpoint of radiographic progression-free survival (rPFS) versus abiraterone and ADT with placebo in patients with PTEN-deficient de novo metastatic hormone-sensitive prostate cancer (mHSPC). Overall survival (OS) data were
Source: www.astrazeneca.comCategories: General Medicine News, Hem/OncsTweet-
Truqap combination in PTEN-deficient metastatic HSPC demonstrated statistically significant and clinically meaningful improvement in radiographic progression-free survival in CAPItello-281 Ph III trial 👏👏 @GuardConsortium @OncoAlert https://t.co/cHKC2ddkmy
-
-
Mashup Score: 65
Positive high-level results from the CAPItello-281 Phase III trial showed that AstraZeneca’s Truqap (capivasertib) in combination with abiraterone and androgen deprivation therapy (ADT) demonstrated a statistically significant and clinically meaningful improvement in the primary endpoint of radiographic progression-free survival (rPFS) versus abiraterone and ADT with placebo in patients with PTEN-deficient de novo metastatic hormone-sensitive prostate cancer (mHSPC). Overall survival (OS) data were
Source: www.astrazeneca.comCategories: General Medicine News, Hem/OncsTweet-
Truqap combination in PTEN-deficient metastatic HSPC demonstrated statistically significant and clinically meaningful improvement in radiographic progression-free survival in CAPItello-281 Ph III trial 👏👏 @GuardConsortium @OncoAlert https://t.co/cHKC2ddkmy
-
-
Mashup Score: 5Episode 369: Paper of the Month with Bishoy Faltas by The Uromigos - 4 month(s) ago
Bishoy joins us to discuss his work on extrachromosomal DNA in bladder cancer from his latest Nature publication
Source: spotifycreators-web.app.linkCategories: General Medicine News, Hem/OncsTweet-
RT @Uromigos: @FaltasLab wins Paper of the Month for fascinating work on extrachromosomal DNA in #BladderCancer! https://t.co/a43aZYq0y0 ht…
-
Excellent collaboration job of our GU working group! @OncoAlert @H12Octubre Full article: Characterisation of the tumour microenvironment and PD-L1 granularity reveals the prognostic value of cancer-associated myofibroblasts in non-invasive bladder cancer https://t.co/26LAgaNrBj